New substituted 1,4-benzoxazine derivatives with potential intracellular calcium activity

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3142-3158

  Bourlot, Anne Sophie ^a   Sánchez, Isabel ^b   Dureng, Georges ^c   Guillaumet, Gérald ^a   Massingham, Roy ^c,d   Monteil, André ^c   Winslow, Eileen ^c   Pujol, M Dolors ^b   Mérour, Jean Yves ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CERM Centre Europeen de Recherches Mauvernay   (France)

^d UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL 3,4 DIHYDRO 2 [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]AMINO]PROPYL] 2H 1,4 BENZOXAZINE; BENZOXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; CALCIUM; CALCIUM CHANNEL BLOCKERS; DRUG DESIGN; MALE; MOLECULAR STRUCTURE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; OXAZINES; PHENYLEPHRINE; RABBITS; RENAL ARTERY; SECOND MESSENGER SYSTEMS; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTION;

EID: 0032514546     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970795t     Document Type: Article

References (53)

1. Ross, E. M. Mechanisms of Drug Action and the Relationship between Drug Concentration and Effect. In The Pharmacological Basis of Therapeutics, 9th ed.; Gilman, A. G., Goodman, L. S., Hardman, J. G., Limbird, L. E., Eds; McGraw-Hill: New York, 1996; pp 29-41.
2. Rasmussen, H.; Goodman, D. B. P. Relationships between Calcium and Cyclic Nucleotides in Cell Activation. Physiol. Rev. 1977, 17, 421-509.
3. Werner, M. H.; Bielawska, A. E.; Hannun, Y. A. Qualitative Analysis of Diacylglycerol Second Messengers in Human Platelets: Correlation with Aggregation and Secretion. J. Pharmacol. Exp. Ther. 1992, 41, 382-386.
4. 2+-Release during Drug Activation of the Rabbit Aorta. Pflugers Arch. 1974, 348, 13-19.
5. Bou J.; Llenas, J.; Massingham, R. Calcium Entry Blocking Drugs, "Calcium Antagonists" and Vascular Smooth Muscle Function. J. Auton. Pharmacol. 1983, 3, 219-232.
6. Spedding, M.; Frazer, S.; Clarke, B.; Patmore, L. Factors Modifying the Tissue Selectivity of Calcium Antagonists. J. Neural. Transm. 1990, 31 (Suppl.), 5-16.
7. 2+ Channels. Trends Pharmacol. Sci. 1991, 12, 349-354.
8. Berridge, M. J. Inositol Triphosphate and Calcium Signalling. Nature 1993, 361, 315-325.
9. Nishizuka, Y. Studies and Perspectives of Protein Kinase C. Science 1986, 233, 305-312.
10. Labrid, C.; Grosset, A.; Dureng, G.; Mironneau, J.; Duchêne-Marullaz, P. Some Membrane Interactions with Bepridil, a New Antianginal Agent. J. Pharmacol. Exp. Ther. 1979, 211, 546-554.
11. Lugnier, C.; Follenius, A.; Gerard, D.; Stoclet, J. C. Bepridil and Flunarizine as Calmodulin Inhibitors. Eur. J. Pharmacol. 1984, 98, 157-158.
12. 2+ Antagonists in the Treatment of Coronary Heart Disease. J. Mol. Cell. Cardiol. 1987, 19 (Suppl. 11), S57.
13. Vogel, S.; Crampton, R.; Sperelakis, N. Blockade of Myocardial Slow Channels by Bepridil. J. Pharmacol. Exp. Ther. 1979, 210, 378-385.
14. Fleckenstein, A. History of Calcium Antagonists. Circ. Res. 1983, 52 (Suppl. 1), 3-16.
15. Massingham, R.; Van Zwieten P. A. Bepridil: A Pharmacological Reappraisal of its Potential Effects in Angina and Tissue Protection Following Ischaemia. Cardiovasc. Drugs Ther. 1989, 3, 731-742.
16. Flaim, S. F.; Ratz, P. H.; Swigart, S. C.; Gleason, M. M. Bepridil Hydrochloride Alters Potential-Dependent and Receptor-Operated Channels in Vascular Smooth Muscle. J. Pharmacol. Exp. Ther. 1985, 234, 63-71.
17. Itoh, H.; Ishikawa, T.; Hidaka, H. Effects on Calmodulin of Bepridil, an Antianginal Agent. J. Pharmacol. Exp. Ther. 1984, 230, 737-741.
18. (a) John, G. W.; Fabrègues, E.; Kamal, M.; Massingham, R. Caffeine-Induced Contractions in Rabbit Isolated Renal Artery are Differentially Inhibited by Calcium Antagonists. Eur. J. Pharmacol. 1991, 196, 307-312.
19. (b) Massingham, R.; Leboeuf, J.; John, G. Sites d'Action Intracellulaire du Bépridil: Place par Rapport aux Autres Antagonistes du Calcium. (Intracellular Action Sites of Bepridil: Comparison with Other Calcium Antagonists.) Lett. Pharmacol. 1989, 3, 1-6.
20. Ross, R. The Pathogenesis of Atherosclerosis: a Perspective for the 1990's. Nature 1993, 362, 801-808.
21. Davies, M. J. Pathogenesis of Atherosclerosis. Curr. Opin. Cardiol. 1992, 7, 541-545.
22. Davies, M. J. The Contribution of Thrombosis to the Clinical Expression of Coronary Atherosclerosis. Thromb. Res. 1996, 82, 1-32.
23. Peto, R. Aspirin and Other Antiplatelet Agents in the Secondary and Primary Prevention of Cardiovascular Disease. Circulation 1989, 80, 749-756.
24. Jang, I. K.; Fuster, V.; Gold, H. K. Antiplatelets. Coron. Artery Dis. 1992, 3, 1030-1036.
25. Feinstein, M. B. Platelets, Macrophages and Neutrophils. In Inositol Lipids in Cell Signalling; Michel, R. H., Drummond, A. H., Downes, C. P., Eds.; Academic Press: London, 1989; pp 247-281.
26. Spedding, M. Calcium Antagonist Subgroups. Trends Pharmacol. Sci. 1985, 6, 109-114.
27. Vanhoutte, P. M. The Expert Committee of the World Health Organization on Classification of Calcium Antagonists: The Viewpoint of the Rapporteur. Am. J. Cardiol. 1987, 59, 3A-8A.
28. Struijker-Boudier, A. J.; Smits, J. F. M.; De Mey, J. G. R. Pharmacology of Cardiac and Vascular Remodelling. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 509-539.
29. Parmley, W. W.; Blumlein, S.; Sievers, R. Modification of Experimental Atherosclerosis by Calcium-Channel Blockers. Am. J. Cardiol. 1985, 55, 165B-171B.
30. Keogh, A. M.; Schroeder, J. S. A Review of Calcium Antagonists and Atherosclerosis. J. Cardiovasc. Pharmacol. 1990, 16 (Suppl. 6), S28-S35.
31. Henry, P. D. Calcium Channel Blockers and Atherosclerosis. J. Cardiovasc. Pharmacol. 1990, 16 (Suppl. 1), S12-S15.
32. Rosenthal, J. Nilvadipine: Profile of a New Calcium Antagonist. An Overview. J. Cardiovasc. Pharmacol. 1994, 24 (Suppl. 2), S92-S107.
33. Vo, D.; Matowe, W. C.; Ramesh, M.; Iqbal, N.; Wolowyk, M. W.; Hewlett, B. E.; Knaus, E. E. Syntheses, Calcium Channel Agonist-Antagonist Modulation Activities, and Voltage-Clamp Studies of Isopropyl 1,4-Dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate Racemates and Enantiomers. J. Med. Chem. 1995, 38, 2851-2859.
34. Campiani, G.; Fiorini, I.; De Filippis, M. P.; Ciani, S. M.; Garofalo, A.; Nacci, V.; Giorgi, G.; Sega, A.; Botta, M.; Chiarini, A.; Budriesi, R.; Bruni, G.; Romeo, M. R.; Manzoni, C.; Mennini, T. Cardiovascular Characterization of Pyrrolo[2,1-d][1,5]Benzothiazepine Derivatives Binding Selectively to the Peripheral-Type Benzodiazepine Receptor (PBR): from Dual PBR Affinity and Calcium Antagonist Activity to Novel and Selective Calcium Entry Blockers. J. Med. Chem. 1996, 39, 2922-2938.
35. Adams, T. C.; Dupont, A. C.; Carter, J. P.; Kachur, J. F.; Guzewska, M. E.; Rzeszotarski, W. J.; Farmer, S. G.; Noronha-Blob, L.; Kaiser, C. Aminoalkynyldithianes. A New Class of Calcium Channel Blockers. J. Med. Chem. 1991, 34, 1585-1593.
36. Iqbal, N.; Knaus, E. E. Synthesis and Smooth Muscle Calcium Channel Antagonist Effects of Alkyl 1,4-dihydro-2,6-dimethyl-4-pyridinyl-5-[2-(4,5-dihydro-4,4-dimethyloxazolin-2- yl)]-3- pyridinecarboxylates. Arch. Pharm. (Weinheim) 1996, 329, 408-412.
37. 2+ Channels and Protein Kinase C. Mol. Endocrinol. 1996, 10, 90-99.
38. Suzuki, T.; Ohashi, M.; Taaiti, O.; Harigaya, S. Calmodulin Antagonist Action of a New 1,5- Benzothiazepines Derived from Diltiazem. Arzneim.-Forsch 1994, 44, 3-6.
39. Asano T.; Hidaka H. New Pharmacological Strategies in Vascular Diseases. A Novel Intracellular Calcium Antagonist, HA-1077 (AT-877) and Cerebral Vasospasm. Methods Find. Exp. Clin. Pharmacol. 1990, 12, 443-448.
40. Inagaki, M.; Tanaka, T.; Hidaka, H. Calmodulin Antagonists Enhance Calcium Binding to Calmodulin. Pharmacology 1983, 27, 125-129.
41. Kajino, M.; Shibouta, Y.; Nishikawa, K.; Meguro, K. Synthesis and Biological Activities of New 2-Substituted 1,4-Benzoxazine Derivatives. Chem. Pharm. Bull. 1991, 39, 2896-2905.
42. Besson, T., Ruiz, N., Coudert, G., Guillaumet, G. Synthesis of a Benzodioxinic Analog of 8-Methoxypsoralen. Tetrahedron 1995, 55, 3197-3204.
43. Thiéry, V.; Coudert, G.; Guillaumet, G. Convenient Synthesis of 2,2-Disubstituted-2,3-Dihydro-1,4-Benzodioxins from 2-Substituted-2-Hydroxy-2,3-Dihydro-1,4-Benzodioxins. Tetrahedron 1997, 53, 2061-2074.
44. Khatib, S.; Mamai, A.; Coudert, G.; Bouzoubaa, M.; Guillaumet, G. Synthesis of 3-Arylbenzo[1,4]dioxin-2-carboxamides by Palladium-Catalysed Coupling of Vinylstannanes with Aryl Halides. Tetrahedron Lett. 1997, 38, 5993-5996.
45. Guillaumet, G.; Loubinoux, B.; Coudert, G. Synthèse de Benzoxazines-1,4. (Synthesis of Benzoxazines.) Tetrahedron Lett. 1978, 2287-2288.
46. Bourlot, A. S.; Guillaumet, G.; Mérour, J. Y. A Straightforward Route to 4H-1,4-Benzoxazin-2-Carbaldehydes. J. Heterocycl. Chem. 1996, 33, 191-196.
47. Coudert, G., Guillaumet, G., Loubinoux, B. A New Synthesis of 3,4-Dihydro-2H-1,4-Benzoxazines using Solid-Liquid Phase-Transfer Catalysis. Synthesis 1979, 541-543.
48. Augstein, J.; Monro, A. M.; Hessey, G. W. G. B. Patent 1.057.568, 1967; Chem. Abstr. 1967, 66, 95058z.
49. Masuoka, Y.; Asako, T.; Goto, G.; Noguchi, S. Syntheses of 3,4-Dihydro-2H-1,4-Benzoxazine-2-Acetates and Related Compounds. Chem. Pharm. Bull. 1986, 34, 130-139.
50. Morikawa, A.; Sone, T.; Asano, T. 5-Isoquinolinesulfonamide Derivatives. 1. Synthesis and Vasodilatory Activity of N-(2-Guanidinoethyl)-5-Isoquinolinesulfonamide Derivatives. J. Med. Chem. 1989, 32, 42-46.
51. Harpp, D. N.; Bao, L. Q.; Black, C. J.; Gleason, J. G.; Smith, R. A. An Efficient α-Halogenation of Acyl Chloride by N-Bromosuccinimide, N-Chlorosuccinimide and Molecular Bromine. J. Org. Chem. 1975, 40, 3420-3427.
52. Fling, M.; Minard, F. N.; Fox, S. W. Prolyl and Phthalyl Derivatives of Enantiomorphs of Valine and Leucine. J. Am. Chem. Soc. 1947, 69, 2466-2470.
53. Winslow, E.; Farmer, S.; Martorana, M.; Marshall, R. J. The Effects of Bepridil Compared with Calcium Antagonists on Rat and Rabbit Aorta. Eur. J. Pharmacol. 1986, 131, 219-228.